A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
Titel:
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
Auteur:
Whang, Young E. Armstrong, Andrew J. Rathmell, W. Kimryn Godley, Paul A. Kim, William Y. Pruthi, Raj S. Wallen, Eric M. Crane, Jeffrey M. Moore, Dominic T. Grigson, Gayle Morris, Karla Watkins, Catharine P. George, Daniel J.